RENALYTIX AI PLC LS-,0025

Action · GB00BYWL4Y04 · A2N765 (XLON)

Aperçu

Analyse alimentée par l’IA

Analyse fondamentale

Découvrez ce que disent vraiment les chiffres — avant le marché

Analyser maintenant

Sentiment des actualités

Les actualités d’aujourd’hui sont-elles un signal d’achat ou un avertissement ?

Analyser maintenant

Acheter / Conserver / Vendre

Faut-il acheter, conserver ou vendre ? Obtenez l’avis de l’IA dès maintenant.

Analyser maintenant

Évaluation des risques

Détectez les risques cachés avant qu’ils n’impactent votre portefeuille.

Analyser maintenant

Juste valeur

Cette action est-elle bon marché, correctement valorisée ou surévaluée ?

Analyser maintenant

Dernières analyses d’IA sur RENALYTIX AI PLC LS-,0025

Pas de cours

Cours de clôture XLON 29.04.2026: 1,79 GBX

29.04.2026 14:33

Cours actuels de RENALYTIX AI PLC LS-,0025

Bourse	Ticker	Devise	Dernier échange	Cours	Variation journalière
London	RENX.L	GBX	29.04.2026 14:33	1,79 GBX	-0,02 GBX -0,83 %

Fonds investis

Les fonds suivants ont investi dans RENALYTIX AI PLC LS-,0025 :

Fonds iShares MSCI UK Small Cap UCITS ETF GBP (Acc)	Vol. en millions 593,21	Part (%) 0,10 %

Profil de l'entreprise pour RENALYTIX AI PLC LS-,0025 Action

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is headquartered in New York, New York.